Prompt initiation of anti-TB drugs, including isoniazid, rifampicin, pyrazinamide, and ethambutol, targets the underlying infection and subsequently reduces systemic inflammation by decreasing the release of pro-inflammatory cytokines such as IL-6. The gene discussed is IL6; the disease is tuberculosis.